Summary
Global Markets Direct’s, ‘Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016’, provides an overview of the Dry (Atrophic) Macular Degeneration pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration
- The report reviews pipeline therapeutics for Dry (Atrophic) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dry (Atrophic) Macular Degeneration therapeutics and enlists all their major and minor projects
- The report assesses Dry (Atrophic) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dry (Atrophic) Macular Degeneration
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dry (Atrophic) Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Aciont Inc.
Acucela Inc.
Alimera Sciences, Inc.
Allergan Plc
Apellis Pharmaceuticals, Inc.
Astellas Pharma Inc.
Benitec Biopharma Limited
Biophytis SAS
Catalyst Biosciences, Inc.
Cell Cure Neurosciences, Ltd.
Foamix Pharmaceuticals Ltd.
Genentech, Inc.
GenSight Biologics S.A.
GlaxoSmithKline Plc
Icon Bioscience, Inc.
Johnson & Johnson
Kodiak Sciences, Inc.
MacuCLEAR, Inc.
Novartis AG
Ophthotech Corp.
Orphagen Pharmaceuticals, Inc.
pSivida Corp.
Sucampo Pharmaceuticals, Inc.
Sun Pharma Advanced Research Company Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Dry (Atrophic) Macular Degeneration Overview 11
Therapeutics Development 12
Pipeline Products for Dry (Atrophic) Macular Degeneration – Overview 12
Pipeline Products for Dry (Atrophic) Macular Degeneration – Comparative Analysis 13
Dry (Atrophic) Macular Degeneration – Therapeutics under Development by Companies 14
Dry (Atrophic) Macular Degeneration – Therapeutics under Investigation by Universities/Institutes 16
Dry (Atrophic) Macular Degeneration – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Dry (Atrophic) Macular Degeneration – Products under Development by Companies 21
Dry (Atrophic) Macular Degeneration – Products under Investigation by Universities/Institutes 23
Dry (Atrophic) Macular Degeneration – Companies Involved in Therapeutics Development 24
Aciont Inc. 24
Acucela Inc. 25
Alimera Sciences, Inc. 26
Allergan Plc 27
Apellis Pharmaceuticals, Inc. 28
Astellas Pharma Inc. 29
Benitec Biopharma Limited 30
Biophytis SAS 31
Catalyst Biosciences, Inc. 32
Cell Cure Neurosciences, Ltd. 33
Foamix Pharmaceuticals Ltd. 34
Genentech, Inc. 35
GenSight Biologics S.A. 36
GlaxoSmithKline Plc 37
Icon Bioscience, Inc. 38
Johnson & Johnson 39
Kodiak Sciences, Inc. 40
MacuCLEAR, Inc. 41
Novartis AG 42
Ophthotech Corp. 43
Orphagen Pharmaceuticals, Inc. 44
pSivida Corp. 45
Sucampo Pharmaceuticals, Inc. 46
Sun Pharma Advanced Research Company Ltd. 47
Dry (Atrophic) Macular Degeneration – Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Target 49
Assessment by Mechanism of Action 51
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
APL-2 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
avacincaptad pegol sodium - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
BIO-201 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BIO-203 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
brimonidine tartrate implant - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CLG-561 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
CNTO-2476 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Drug for Age Related Macular Degeneration - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Drug for Wet AMD and Dry AMD - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
EG-30 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
emixustat hydrochloride - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
fluocinolone acetonide SR - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
FMX-103 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Gene Therapy for Ocular Diseases - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
GS-030 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
GSK-933776 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
ICR-14967 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
KSI-401 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
lampalizumab - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
MA09-hRPE - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
MC-1101 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
methotrexate - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
OCU-100 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
ONL-1204 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
OpRegen - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
OpRegen Plus - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
RC-1 Alpha - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
RST-001 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Small Molecules for AMD - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Small Molecules for Dry Age-Related Macular Degeneration - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
tesidolumab - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
TT-231 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
unoprostone isopropyl - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
VM-100 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Dry (Atrophic) Macular Degeneration – Recent Pipeline Updates 107
Dry (Atrophic) Macular Degeneration - Dormant Projects 130
Dry (Atrophic) Macular Degeneration – Discontinued Products 132
Dry (Atrophic) Macular Degeneration – Product Development Milestones 133
Featured News & Press Releases 133
May 05, 2016: RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences 133
Nov 17, 2015: Biophytis establishes New subsidiary to accelerate clinical development of Maculia 133
Sep 28, 2015: Alimera Sciences Announces Availability Of Review Paper On Real World Experience With ILUVIEN 133
Oct 18, 2013: Alimera Sciences Receives Complete Response Letter For ILUVIEN 134
Oct 01, 2013: Roche to present data on Lampalizumab at investor event 135
Aug 27, 2013: Roche’s lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration 136
Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials 137
May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells 138
Apr 15, 2013: ACT Treats First Patient With Better Vision In Clinical Trial For Stargardt’s Macular Dystrophy 138
Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy 139
Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 140
Contact Us 140
Disclaimer 141
List of Tables
Number of Products under Development for Dry (Atrophic) Macular Degeneration, H1 2016 12
Number of Products under Development for Dry (Atrophic) Macular Degeneration – Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Number of Products under Development by Companies, H1 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Development, H1 2016 19
Comparative Analysis by Unknown Stage Development, H1 2016 20
Products under Development by Companies, H1 2016 21
Products under Development by Companies, H1 2016 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2016 23
Dry (Atrophic) Macular Degeneration – Pipeline by Aciont Inc., H1 2016 24
Dry (Atrophic) Macular Degeneration – Pipeline by Acucela Inc., H1 2016 25
Dry (Atrophic) Macular Degeneration – Pipeline by Alimera Sciences, Inc., H1 2016 26
Dry (Atrophic) Macular Degeneration – Pipeline by Allergan Plc, H1 2016 27
Dry (Atrophic) Macular Degeneration – Pipeline by Apellis Pharmaceuticals, Inc., H1 2016 28
Dry (Atrophic) Macular Degeneration – Pipeline by Astellas Pharma Inc., H1 2016 29
Dry (Atrophic) Macular Degeneration – Pipeline by Benitec Biopharma Limited, H1 2016 30
Dry (Atrophic) Macular Degeneration – Pipeline by Biophytis SAS, H1 2016 31
Dry (Atrophic) Macular Degeneration – Pipeline by Catalyst Biosciences, Inc., H1 2016 32
Dry (Atrophic) Macular Degeneration – Pipeline by Cell Cure Neurosciences, Ltd., H1 2016 33
Dry (Atrophic) Macular Degeneration – Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 34
Dry (Atrophic) Macular Degeneration – Pipeline by Genentech, Inc., H1 2016 35
Dry (Atrophic) Macular Degeneration – Pipeline by GenSight Biologics S.A., H1 2016 36
Dry (Atrophic) Macular Degeneration – Pipeline by GlaxoSmithKline Plc, H1 2016 37
Dry (Atrophic) Macular Degeneration – Pipeline by Icon Bioscience, Inc., H1 2016 38
Dry (Atrophic) Macular Degeneration – Pipeline by Johnson & Johnson, H1 2016 39
Dry (Atrophic) Macular Degeneration – Pipeline by Kodiak Sciences, Inc., H1 2016 40
Dry (Atrophic) Macular Degeneration – Pipeline by MacuCLEAR, Inc., H1 2016 41
Dry (Atrophic) Macular Degeneration – Pipeline by Novartis AG, H1 2016 42
Dry (Atrophic) Macular Degeneration – Pipeline by Ophthotech Corp., H1 2016 43
Dry (Atrophic) Macular Degeneration – Pipeline by Orphagen Pharmaceuticals, Inc., H1 2016 44
Dry (Atrophic) Macular Degeneration – Pipeline by pSivida Corp., H1 2016 45
Dry (Atrophic) Macular Degeneration – Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 46
Dry (Atrophic) Macular Degeneration – Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 47
Assessment by Monotherapy Products, H1 2016 48
Number of Products by Stage and Target, H1 2016 50
Number of Products by Stage and Mechanism of Action, H1 2016 52
Number of Products by Stage and Route of Administration, H1 2016 54
Number of Products by Stage and Molecule Type, H1 2016 56
Dry (Atrophic) Macular Degeneration Therapeutics – Recent Pipeline Updates, H1 2016 107
Dry (Atrophic) Macular Degeneration – Dormant Projects, H1 2016 130
Dry (Atrophic) Macular Degeneration – Dormant Projects (Contd..1), H1 2016 131
Dry (Atrophic) Macular Degeneration – Discontinued Products, H1 2016 132
List of Figures
Number of Products under Development for Dry (Atrophic) Macular Degeneration, H1 2016 12
Number of Products under Development for Dry (Atrophic) Macular Degeneration – Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Products, H1 2016 19
Assessment by Monotherapy Products, H1 2016 48
Number of Products by Top 10 Targets, H1 2016 49
Number of Products by Stage and Top 10 Targets, H1 2016 49
Number of Products by Top 10 Mechanism of Actions, H1 2016 51
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 51
Number of Products by Routes of Administration, H1 2016 53
Number of Products by Stage and Routes of Administration, H1 2016 53
Number of Products by Top 10 Molecule Types, H1 2016 55
Number of Products by Stage and Top 10 Molecule Types, H1 2016 55
